Market Overview

Global Pharmaceutical Spray Drying Market to 2028: Insightful 2X2 Analysis of Different Spray Drying Service Providers


Global Pharmaceutical Spray Drying Market to 2028: Insightful 2X2 Analysis of Different Spray Drying Service Providers

PR Newswire

DUBLIN, Sept. 13, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Pharmaceutical Spray Drying Market (2nd Edition), 2018-2028" report has been added to's offering

The Pharmaceutical Spray Drying Market (2nd Edition), 2018-2028' report provides an extensive study on the use of spray drying in the pharmaceutical sector. The key focus of the report is primarily to estimate the future potential of spray drying in the manufacturing of APIs, inhalables, injectables, biologics and other pharmaceutical products. The study presents an in-depth analysis of a diverse set of companies that provide spray drying equipment and services across different regions of the globe.

It offers several advantages over alternate drying technologies, such as lyophilization (characterized by high dependence on cold chain for storage and logistics, which is prone to failure due to human error) and vacuum foam drying (characterized by volumetric restrictions due to the properties of foam, which limits the quantity of sample that can be dried in a single run) that are currently deployed in the pharmaceutical industry.

Amongst other merits, spray drying is known to be suitable for drying heat-sensitive products such as biologics. Moreover, this method imparts improved properties to the formulations that can be administered through more efficient and less invasive modes of delivery, such as oral, and inhalation routes. The technology also aids in improving the compression properties of drugs, allowing developers to design concentrated dose variants of medications and reduce tablet size. Such alterations have the potential to improve patient compliance. Given the flexibility offered in terms of drug development and formulation, the economics of the technique, the introduction of aseptic methods, and the recent approval of the first spray dried biologic, Raplixa, the adoption of spray drying is anticipated to increase steadily in the pharmaceutical industry.

Amongst other elements, the report includes:

  • A detailed discussion the applications of spray drying in the pharmaceutical industry; these include enhancement of solubility and bioavailability, formulation of inhalables, taste masking, development of controlled release formulations, and aseptic production of biopharmaceuticals.
  • An assessment of the various players that are engaged in the manufacturing of spray dryers used in the pharmaceutical industry, including a detailed analysis of their products based on inlet temperature, type of nozzle (fluid, pressure, rotary disc, centrifugal and others), size of the dryer (lab, clinical and commercial) and atomizing gas (air, nitrogen and inert gases).
  • An overview of the current market landscape of spray drying service providers, featuring an analysis based on the location of their operating facilities, type of spray dryers used, scale of operation (lab, clinical and commercial), information on cGMP status of their facilities and availability of fill/finish services.
  • An insightful 2X2 analysis of different spray drying service providers. This analysis is based on the spray drying capabilities (represented in terms of number of manufacturing sites, scale of operation and the types of spray dryers used) and the company size. In addition, similar analysis has been done to compare the spray dryer manufacturers. This assessment is based on the company's spray drying portfolio (number of spray dryers offered and availability of spray drying services), company's year of establishment and the geographical coverage of its client base.
  • Tabulated profiles of the players offering spray drying services, featuring company overview, service portfolio, spray dryers used, and key developments related to its spray drying capabilities.
  • Detailed profiles of spray dryer manufacturers, featuring an overview of the company, its financial information (if available), types of spray dryers in their respective product portfolios, recent developments and a comprehensive future outlook.
  • A case study on the lyophilization of biologics, highlighting the underlying process, its applications, and merits and demerits. It features a detailed list of companies offering lyophilization services with information on location of facilities, types of drug candidates lyophilized, scale of operation and the containment systems utilized for such operations.
  • A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis highlights the ownership change matrix and presents financial evaluation of these deals (revenues and respective deal multiples).
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework.

Key Topics Covered:

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines


3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional CMOs
3.4.2. Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Software Service Providers
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry

4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered

5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Bubble Analysis: Regional Regulatory Summary

6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops
6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.2. Catalent Pharma Solutions
6.4.3. DPT Laboratories
6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon)
6.5. Players in Europe
6.5.1. Aenova Group
6.5.2. Almac Group
6.5.3. CordenPharma
6.5.4. Fresenius Kabi
6.5.5. Glatt
6.5.6. Groupe SYNERLAB
6.5.7. Hovione
6.5.8. Recipharm
6.5.9. Siegfried
6.6. Players in Asia-Pacific
6.6.1. CMIC Group
6.6.2. Nectar Lifesciences
6.6.3. WuXi AppTec

7.1. Chapter Overview
7.2. Small Molecules and Large Molecules Drugs/Therapies
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs

8.1. Chapter Overview
8.2. Multipotentialite Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment

9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks



12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Expansion of Capabilities and Emergence of One-Stop-Shops
12.5. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.6. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.7. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.8. Concluding Remarks

13.1. Chapter Overview
13.2. Ajinomoto Althea
13.3. Bachem
13.4. Sovereign Pharma
13.5. Batavia Biosciences
13.6. Polymun Scientific
13.7. Rentschler Biopharma
13.8. WACKER Biotech
13.9. CiVentiChem
13.10. CordenPharma
13.11. Helsinn Group
13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals



For more information about this report, visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content to download multimedia:

SOURCE Research and Markets

View Comments and Join the Discussion!